Answers are grounded in this paper and cite their sources.
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) has a substantial risk of recurrence despite multimodal treatment. Mutation-derived neoepitopes provide a rationale for personalized vaccination, but their clinical relevance depends on target expression and clonality, effective antigen presentation, and access of functional T cells to malignant cells. This narrative review distinguishes direct HPV-negative HNSCC evidence from HNSCC-inclusive programs, shared-antigen comparators, target-selection technologies, and cross-tumor studies. The randomized phase I TG4050 study in 33 patients with resected HPV-negative HNSCC supports feasibility and immunogenicity; its small sample, few recurrence events, and per-protocol recurrence analysis preclude definitive efficacy conclusions. Complementary translational and cross-tumor studies inform antigen selection, vaccine delivery, and combination strategies, with uncertain transferability to HPV-negative HNSCC. We examine the separate evidentiary requirements for predicted targets, natural human leukocyte antigen (HLA) presentation, T-cell recognition, tumor-cell killing, and clinical benefit. We discuss spatial immune profiling to investigate resistance and circulating tumor DNA to monitor disease, while emphasizing that their roles in guiding vaccination remain exploratory. Future studies should define the treatment setting, evaluate whether vaccination adds benefit to contemporary standard treatment, report manufacturing attrition and time to first dose, and connect standardized immune measurements with clinical outcomes. Personalized neoepitope vaccination remains investigational in HPV-negative HNSCC, and adequately powered randomized trials are required to establish its clinical role.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: